로딩 중...
52주 최고가 대비 74.9% 위치
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
SEC 13F 공시 기준 · 2026-Q1
SEC 13F 공시 기준 데이터입니다. 실제 현재 보유 현황과 다를 수 있으며, 투자 자문·권유·추천이 아닙니다.
| 재무 항목 | 2022년 | 2023년 | 2024년 | 2025년 |
|---|---|---|---|---|
| 주요 재무실적 (USD) | ||||
| 매출액 | $44.91B | $42.86B | $42.88B | $44.56B |
| 영업이익 | $8.51B | $7.32B | $7.72B | $8.11B |
| 당기순이익 | $6.95B | $6.00B | $6.33B | $6.70B |
| 잉여현금흐름 (FCF) | $6.91B | $6.93B | $7.27B | $6.29B |
| 수익성 비율 | ||||
| 영업이익률 | 18.9% | 17.1% | 18.0% | 18.2% |
| 순이익률 | 15.5% | 14.0% | 14.8% | 15.0% |
| ROE (자기자본이익률) | 15.8% | 12.8% | 12.8% | 12.6% |
| ROA (자산이익률) | 7.2% | 6.1% | 6.5% | 6.1% |
| 성장성 비율 | ||||
| 매출 성장률 (YoY) | - | -4.6% | 0.1% | 3.9% |
| EPS 성장률 (YoY) | - | -12.4% | 7.0% | 7.3% |
| 투자 지표 & 가치배수 | ||||
| PER (주가수익배수) | 32.0x | 34.6x | 36.0x | 32.6x |
| PBR (주가순자산배수) | 4.8x | 4.3x | 4.5x | 4.0x |
| PSR (주가매출배수) | 4.7x | 4.6x | 5.2x | 4.8x |
| FCF Yield | 3.3% | 3.5% | 3.3% | 2.9% |
| 재무 건전성 (안정성) | ||||
| 부채비율 (D/E) | 0.78 | 0.75 | 0.63 | 0.74 |
| 유동비율 | 1.48 | 1.75 | 1.66 | 1.89 |
MOLINA HEALTHCARE INC
$179.86
$9.4B